Mrna

Pic:getty/tetianagarkusha

mRNA tech ‘reason for hope’ on path to HIV vaccine

By Ben Hargreaves

With mRNA tech achieving major success against COVID-19, the initiation of trials into vaccination against HIV is creating discussion amid a potential breakthrough in the prevention of the disease.

Pic:getty/coffeekai

Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

Two of the new vaccine candidates target latent viruses. Pic:getty/artemisdiana

Moderna targets shingles in mRNA pipeline expansion

By Rachel Arthur

Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.

Pic:getty/remotevtx

Pfizer sets out strategy to win in mRNA

By Rachel Arthur

Having built up its mRNA expertise with its COVID-19 vaccine, Pfizer now sets out its strategy for the future. “Going forward, we plan to continue to capitalize on the leadership we have built in both mRNA R&D and manufacturing."

© GettyImages/niphon

Moderna to develop mRNA therapeutic for very rare disease

By Jane Byrne

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Pic:getty/richarddrury

mRNA and beyond: Opportunities for US biologics

By Staff reporter

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

© GettyImages/Fokusiert

Moderna starts process to obtain BLA for Covid-19 shot

By Jane Byrne

Moderna has initiated the rolling submission process with the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) to distribute and market its mRNA COVID-19 vaccine in the US for use in individuals aged 18 and older.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers